ADDvise reports interim report for the first half of 2026
Revenue fell by 11.1 percent while order intake increased by 1.6 percent. Cash flow from ongoing operations improved significantly by 58.7 percent.
See the latest news and media coverage for ADDvise. We track all announcements, press releases, and industry mentions in real time, all in one place.
Supplier of products and services to healthcare and research units
addvisegroup.seLast updated
In short: ADDvise applied for delisting after Amplex takeover and posted lower revenue with stronger cash flow.
Revenue fell by 11.1 percent while order intake increased by 1.6 percent. Cash flow from ongoing operations improved significantly by 58.7 percent.
Q2 2026 net revenue fell 6.1% to SEK 372.0 million, while order intake rose 0.6%. EBITA dropped 31.9% and loss was SEK -14.0 million. Operating cash flow increased 158.5%.
Net revenue fell 15.7% and EBITA declined; orders grew 2.6% and Amplex acquired over 99% leading to delisting.
The annual report is available in Swedish and English; the sustainability report in Swedish. Both are on the website.
Pareto lowers the recommendation for the medtech group Addvise Group to hold from buy and lowers the target price to 1.72 kronor from 2. The analysis house states that the preliminary results...
Få har nappat på Amplex bud på Addvise - premien höjs Få aktieägare i Addvise har nappat på Amplex bud på att köpa ut bolaget...
At the extraordinary general meeting in ADDvise Group AB (publ) ("ADDvise") held today on 16 February 2026, Mia Tomczak and Richard Jernberg were elected as...
On 10 December 2025, Amplex AB ("Amplex" or the "Bidder") announced a public offer to the holders of shares and warrants in ADDvise Group AB...
Track ADDvise and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to ADDvise and other trending companies.